The antiphospholipid syndrome is a prothrombotic disorder associated with autoantibodies.
It is associated with obstetrical complications (mainly spontaneous abortion) as well as …

The antiphospholipid syndrome (APS) is defined by the presence of anti-phospholipid
antibodies (aPLs) and venous or arterial thrombosis, recurrent pregnancy loss, or …

Given the immense antigenic load present in the microbiome, we hypothesized that
microbiota mimotopes can be a persistent trigger in human autoimmunity via cross-reactivity …

Anticardiolipin antibodies (aCL) derived from the sera of individuals exhibiting the
antiphospholipid syndrome (APS) directly bind to beta 2-glycoprotein I (beta 2-GPI), which is …

Oxidative modification of low-density lipoprotein (LDL) is one of the earliest events in
atherosclerosis. Oxidized LDL (oxLDL) represents a variety of modification of both lipid and …

Anticardiolipin antibodies (aCL) in the sera of patients with antiphospholipid syndrome
(APS) recognize an altered structure of β2-glycoprotein I (β2-GPI) interacting with solid …

The optimal clinical management of patients with antiphospholipid antibody syndrome (APS)
is uncertain because of a lack of an underlying hypothesis to explain why antiphospholipid …

Oxidized low-density lipoprotein (oxLDL) is thought to promote atherosclerosis through
complex inflammatory and immunologic mechanisms that lead to lipid dysregulation and …

β 2-glycoprotein I (β 2-GPI) is a major antigen for antiphospholipid antibodies (Abs, aPL)
present in patients with antiphospholipid syndrome (APS). We recently reported (J. Lipid …

Background—Immunization with β2-glycoprotein I (β2GPI), the probable target of
autoimmune anticardiolipin antibodies, results in experimental antiphospholipid syndrome …